North America Multiple Hereditary Exostosis Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 49.82 Million |
 Market Size (Forecast Year) |
USD 63.46 Million |
 CAGR |
% |
| Major Markets Players |
北美多发性遗传性外生骨疣市场细分，按类型（无蒂和带蒂）、治疗（手术、药物和其他）、诊断（X 射线、计算机断层扫描 (CT)、磁共振成像 (MRI)、基因测试和其他）、部位（腿、手臂、肩膀、骨盆、手指和脚趾）、年龄组（儿童和成人）、最终用户（医院、专科诊所、门诊手术中心和其他） - 行业趋势和预测到 2031 年
多发性遗传性外生骨疣市场分析
MHE 是一种罕见的遗传性疾病，其特征是多发性良性骨肿瘤（骨软骨瘤），严重情况下会导致畸形、疼痛和活动受限。人们对 MHE 和遗传性疾病的认识不断提高，预计将成为市场增长的驱动力。不过，像 palovarotene 这样的先进疗法每年的费用很高，许多患者无法获得有效治疗，尤其是那些缺乏足够保险的患者。这预计将成为市场增长的制约因素。
多发性遗传性外生骨疣市场规模
2023 年北美多发性遗传性外生骨疣市场规模价值 4982 万美元，预计到 2031 年将达到 6346 万美元，2024 年至 2031 年预测期内的复合年增长率为 3.1%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
多发性遗传性外生骨疣市场趋势
“提高人们对基因研究的认识并取得进展”
北美多发性遗传性外生骨疣 (MHE) 市场正在见证一个显著趋势，即提高对该疾病的认识和基因研究的进步。随着医疗保健专业人员和患者对 MHE 的了解越来越多，对准确诊断和有效治疗方案的需求也越来越大。基因检测和分子生物学的科学发展正在增强对 MHE 潜在机制的理解，从而带来个性化医疗方法。此外，加强教育计划和患者宣传工作正在促进有关 MHE 的知识传播，从而鼓励更多人寻求医疗建议。这种转变不仅推动了对专业医疗保健服务的需求，而且还推动了制药行业的增长，各公司正在探索旨在更有效地管理 MHE 的创新疗法和干预措施。总体而言，认识、教育和研究的融合将在未来几年显著塑造 MHE 市场的格局。
报告范围和多发性遗传性外生骨疣市场细分
|
属性 |
多发性遗传性外生骨疣市场洞察 |
|
涵盖的领域 |
|
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
主要市场参与者 |
拜耳公司（德国）、Haleon 集团（英国）、巴斯夫（德国）、Viatris Inc.（美国）、Mallinckrodt（美国）、AdvaCare Pharma（美国）、Aurobindo Pharma（印度）、Taj Pharmaceutical Limited（印度）、Wellona Pharma（印度）和 ActizaPharma（印度）等 |
|
市场机会 |
|
|
增值数据信息集 |
除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察之外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。 |
多发性遗传性外生骨疣市场定义
多发性遗传性外生骨疣 (MHE)，也称为遗传性多发性外生骨疣 (HME)，是一种遗传性疾病，其特征是出现多个良性骨肿瘤，称为外生骨疣或骨软骨瘤。这些肿瘤通常由长骨末端的软骨生长引起，可发生在身体的各个部位。MHE 通常以常染色体显性模式遗传；这意味着只需要一个突变基因的拷贝即可表现出这种疾病。患有 MHE 的人可能会感到疼痛、外生骨疣引起的并发症（如畸形或活动受限），并且患骨肉瘤（一种骨癌）的风险增加。
多发性遗传性外生骨疣市场动态
驱动程序
- 遗传疾病患病率上升
MHE 是一种罕见的遗传性疾病，其特征是多发性良性骨肿瘤（骨软骨瘤），可导致身体畸形、疼痛，严重时甚至行动不便。随着人们对 MHE 和其他遗传性疾病的认识不断提高，对有效诊断和治疗干预的需求也随之激增。
例如，
- 2019 年 12 月，根据美国国立卫生研究院发表的一篇文章，西方人群中 HME（遗传性多发性外生骨疣）的患病率估计为每 50,000 人 0.4 至 1 人。然而，在关岛的查莫罗人中，患病率明显更高，达到每 50,000 人 50 人。据报道，在西方国家，这种疾病的发病率每年增加 1.5%。HME 等遗传性疾病患病率的上升凸显了对有效治疗的需求日益增长，这将推动北美多发性遗传性外生骨疣市场的发展，因为医疗保健系统优先考虑此类疾病的诊断和管理。
随着基因筛查和诊断技术的进步，早期发现 MHE 变得越来越可行，从而可以及时干预并改善患者的治疗效果。基因检测已成为识别携带者和高危人群的重要工具，可实现个性化治疗计划和有针对性的治疗。随着越来越多的医疗保健提供者认识到早期诊断在管理 MHE 等遗传疾病方面的重要性，对此类诊断技术的需求正在增长。
- 儿科人口不断增长
多发性遗传性外生骨疣 (MHE) 主要影响儿童，通常在幼儿期或青春期出现症状。随着北美儿科人口的增长，确诊病例的可能性也随之增加，这直接推动了对早期诊断和有效治疗方案的需求。MHE 可导致骨骼畸形、运动受限和并发症，严重影响儿童的成长和生活质量，因此及时干预至关重要。
例如，
- 2023 年 5 月，据 ScienceDirect 发表的一篇文章称，印度儿科人口不断增长，加上负担能力不断提高，凸显了改善医疗服务的迫切需求。尽管 0 至 18 岁的儿童占总人口的 39%，是该地区最高的比例，但医疗基础设施仍然是一个关键重点。印度庞大的儿科人口凸显了对专业医疗解决方案的需求，推动了北美多发性遗传性外生骨疣市场的发展，因为这个庞大且不断增长的人口对儿科遗传疾病诊断和治疗的需求不断增加。
儿科人口不断增长，尤其是在发展中地区，这导致人们更加关注儿科医疗基础设施。政府和医疗机构认识到需要加强基因筛查计划并提供专门的儿科护理。随着越来越多的儿童被诊断出患有 MHE，对基因检测、定期监测和手术干预以治疗该疾病的需求也在增加。这导致对专门针对儿童的先进诊断工具和治疗方案的需求不断增加。
机会
- 增加病人护理和支持系统
患者护理和支持系统的增加正在显著改变北美多发性遗传性外生骨疣市场。随着全球医疗保健系统强调以患者为中心的护理，对定制治疗和全面支持的需求激增。这一趋势对于多发性遗传性外生骨疣（MHE）尤其重要，这是一种以形成多个良性骨质增生为特征的遗传性疾病。
随着技术的进步和远程医疗的兴起，患者支持系统变得越来越方便和高效。数字平台使患者能够与医疗保健专业人员联系、分享经验并获取宝贵的资源。这些发展可以更好地管理 MHE 症状并促进早期干预，从而减轻并发症。随着患者变得更加知情和有能力，对创新疗法和管理方案的需求可能会增加，这为制药和生物技术公司在 MHE 市场扩大产品供应创造了机会。
- 合作与伙伴关系数量增加
制药公司、研究机构和医疗器械制造商之间的合作伙伴关系和合作激增，为北美多发性遗传性外生骨疣市场带来了重大机遇。这些合作伙伴关系可以通过促进知识共享、专业知识交流和资源共享来加快新型治疗和疗法的开发，从而满足多发性遗传性外生骨疣患者尚未满足的需求。
公司可以通过战略合作伙伴关系将现有技术和疗法结合起来，创造创新解决方案。合作伙伴关系和协作的增加可能会推动对 MHE 研究的投资，进而推动市场创新和增长。随着制药公司和医疗器械制造商与其他组织合作满足 MHE 患者的需求，预计将看到对研发的投资增加，从而更好地了解 MHE 的根本原因并开发更有效的治疗方法。
限制/挑战
- 先进疗法成本高昂
“先进疗法的高成本”对北美多发性遗传性外生骨疣 (MHE) 市场造成了重大制约，因为它对治疗可及性和医疗保健系统产生了多方面的影响。诸如帕洛瓦罗汀等先进疗法每年的费用相当高，使得许多人无法获得有效治疗，尤其是那些没有足够保险的人。如“诊断”部分所述，对 MRI 和 CT 扫描等昂贵诊断工具的依赖增加了经济负担，阻碍了及时治疗，并可能导致更糟糕的健康结果。
例如，
- 2023 年 8 月，根据 NCBI 发表的一篇文章，8 至 14 岁患者每年服用 palovarotene 的费用估计约为 622,373 美元，14 岁及以上患者每年服用 palovarotene 的费用估计约为 1,022,894 美元。这种先进疗法的高成本是北美多发性遗传性外生骨疣市场的主要制约因素，因为沉重的经济负担限制了患者获得治疗的机会，尤其是对于没有足够保险覆盖的患者或医疗资金紧张的地区。
治疗方法有限
有效疗法的有限可用性仍然是北美多发性遗传性外生骨疣市场增长的重大制约因素。尽管研究取得了进展，新兴药物如 palovarotene 也显示出良好的前景，但目前 MHE 的治疗前景仍不成熟。Palovarotene 虽然是一种有希望的治疗方法，但尚未在所有地区广泛使用或获得批准，这限制了其对更广泛患者群体的可及性。
此外，专门针对 MHE 根本病因的药物非常少。大多数现有治疗都侧重于控制症状，例如通过布洛芬等药物缓解疼痛或通过手术切除骨软骨瘤。然而，这些治疗并未解决该疾病的遗传基础，因此患者在长期改善病情的治疗选择方面非常有限。
例如，
- 2019年12月，根据美国国立卫生研究院发表的一篇文章，切除、肢体缩短和手术畸形矫正是目前唯一可用的治疗选择，主要推荐用于有症状的病例或怀疑有恶性转化时。
本市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需获取更多市场信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
多发性遗传性外生骨疣市场范围
市场根据类型、治疗、诊断、部位、年龄组和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 无柄
- 有蒂
治疗
- 外科手术
- 切除肿瘤
- 延长四肢
- 药物
- 医院药房
- 药店和零售药房
- 网上药店
- 其他的
诊断
- X 射线
- 无柄
- 有蒂
- 计算机断层扫描 (CT)
- 无柄
- 有蒂
- 磁共振成像（MRI）
- 无柄
- 有蒂
- 基因测试
- 无柄
- 有蒂
- 其他的
- 无柄
- 有蒂
地点
- 腿
- 武器
- 肩膀
- 骨盆
- 手指
- 脚趾
年龄组
- 儿科
- 成人
最终用户
- 医院
- 私人的
- 政府
- 专科诊所
- 门诊手术中心
- 其他的
多发性遗传性外生骨疣市场区域分析
对市场进行分析，并按上述国家、类型、治疗、诊断、地点、年龄组、最终用户提供市场规模洞察和趋势。
市场覆盖的国家包括美国、加拿大和墨西哥。
美国预计将成为该市场中占主导地位且增长最快的国家，因为其拥有完善的医疗基础设施和高采用率的先进技术，包括基于云的解决方案和自动化。政府的支持性举措和对医疗 IT 的大量投资推动了创新并提高了该地区实验室运营的效率。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了区域品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
多发性遗传性外生骨疣市场份额
市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、区域存在、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
北美多发性遗传性外生骨疣市场领导者有：
- 拜耳公司（德国）
- Haleon 集团公司（英国）
- 巴斯夫（德国）
- Viatris Inc.（美国）
- Mallinckrodt（美国）
- AdvaCare Pharma（美国）
- Aurobindo Pharma（印度）
- 泰姬制药有限公司 (印度)
- Wellona Pharma（印度）
- ActizaPharma（印度）
- Lqms 软件解决方案（美国）
- Starlims Corporation（雅培子公司）（美国）
北美多发性遗传性外生骨疣市场最新动态
- 2023 年 1 月，益普生收购了 Albireo，通过首个获批的治疗进行性家族性肝内胆汁淤积症的药物 Bylvay (odevixibat) 增强了其罕见病产品组合。这一战略举措旨在加速罕见儿童肝病领域的发展，增强益普生的市场占有率，并为医疗资源匮乏的患者提供更多治疗选择。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PIPELINE ANALYSIS - OBSERVATORY DATA
4.4 EPIDEMIOLOGY
5 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: REGULATIONS
5.1 REGULATION IN UNITED STATES: U.S. FOOD AND DRUG ADMINISTRATION (FDA)
5.1.1 REGULATION IN EUROPE: EUROPEAN MEDICINES AGENCY (EMA)
5.2 REGULATION IN ASIA-PACIFIC (JAPAN): PHARMACEUTICAL AND MEDICAL DEVICES AGENCY (PMDA)
5.3 MEDICAL DEVICE STANDARDS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF GENETIC DISORDERS
6.1.2 GROWING PEDIATRIC POPULATION
6.1.3 DEVELOPMENT OF NOVEL THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST OF ADVANCED THERAPIES
6.2.2 LIMITED AVAILABILITY OF THERAPIES
6.3 OPPORTUNITIES
6.3.1 INCREASE IN PATIENT CARE AND SUPPORT SYSTEMS
6.3.2 INCREASE IN THE NUMBER OF COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 LIMITED AWARENESS ABOUT THE DISORDER
6.4.2 LACK OF DRUG APPROVALS ASSOCIATED WITH THE DISORDER
7 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE
7.1 OVERVIEW
7.2 SESSILE
7.3 PEDUNCULATED
8 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY
8.2.1 REMOVE THE TUMOR
8.2.2 LENGTHEN LIMBS
8.3 MEDICATION
8.3.1 HOSPITAL PHARMACIES
8.3.2 DRUGS STORES AND RETAIL PHARMACIES
8.3.3 ONLINE PHARMACIES
8.4 OTHERS
9 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 X-RAY
9.2.1 SESSILE
9.2.2 PEDUNCULATED
9.3 COMPUTED TOMOGRAPHY (CT) SCAN
9.3.1 SESSILE
9.3.2 PEDUNCULATED
9.4 MAGNETIC RESONANCE IMAGING (MRI)
9.4.1 SESSILE
9.4.2 PEDUNCULATED
9.5 GENETIC TESTS
9.5.1 SESSILE
9.5.2 PEDUNCULATED
9.6 OTHERS
9.6.1 SESSILE
9.6.2 PEDUNCULATED
10 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE
10.1 OVERVIEW
10.2 LEGS
10.3 ARMS
10.4 SHOULDERS
10.5 PELVIS
10.6 FINGERS
10.7 TOES
11 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 PEDIATRIC
11.3 ADULT
12 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.2.1 PRIVATE
12.2.2 GOVERNMENT
12.3 SPECIALTY CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 NORTH AMERICA MULTIPLE HEREDITY EXOSTOSIS MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 BAYERS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT UPDATES
16.2 HALEON GROUP OF COMPANIES
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BASF
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT UPDATES
16.4 VIATRIS INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT UPDATES
16.5 ACTIZAPHARMA
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT UPDATES
16.6 ADVACARE PHARMA
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT UPDATES
16.7 AUROBINDO PHARMA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT TABLETS
16.8 HALEON GROUP OF COMPANIES
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT UPDATES
16.9 IPSEN BIOPHARMACEUTICALS, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT UPDATES
16.1 MALLINCKRODT
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT UPDATES
16.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT UPDATES
16.12 TAJ PHARMACEUTICALS LIMITED
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT UPDATES
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 PIPELINE ANALYSIS - OBSERVATORY DATA
TABLE 2 PIPELINE ANALYSIS - INTERVENTIONAL DATA
TABLE 3 SALES DATA - 2024
TABLE 4 SALES DATA - 2023
TABLE 5 SALES DATA - 2022
TABLE 6 SALES DATA - 2021
TABLE 7 SALES DATA - 2020
TABLE 8 SALES DATA - 2019
TABLE 9 SALES DATA - 2018
TABLE 10 COST OF PALOVAROTENE
TABLE 11 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 12 NORTH AMERICA SESSILE IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 NORTH AMERICA PEDUNCULATED IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 15 NORTH AMERICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 NORTH AMERICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 NORTH AMERICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 19 NORTH AMERICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 21 NORTH AMERICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 23 NORTH AMERICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 27 NORTH AMERICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 NORTH AMERICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA LEGS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 NORTH AMERICA ARMS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA SHOULDERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA PELVIS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA FINGERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA TOES IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA PEDIATRIC IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA ADULT IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA SPECIALTY CLINICS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 61 NORTH AMERICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 64 U.S. SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 U.S. MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 66 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 67 U.S. X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 U.S. COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 U.S. GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 U.S. OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 73 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 74 U.S. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 75 U.S. HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 CANADA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 CANADA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 80 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 81 CANADA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 CANADA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 CANADA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 CANADA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 CANADA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 87 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 88 CANADA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 89 CANADA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 92 MEXICO SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 MEXICO MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 94 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 95 MEXICO X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 MEXICO COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 MEXICO MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 MEXICO GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 MEXICO OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 101 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 102 MEXICO MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 103 MEXICO HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 PRODUCT LIFELINE CURVE
FIGURE 9 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 TWO SEGMENTS COMPRISE THE NORTH AMERICA MULTIPLE HEREDITY EXOSTOSIS MARKET, BY TYPE
FIGURE 15 RISING PREVALENCE OF GENETIC DISORDERS IS DRIVING THE GROWTH OF THE NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET FROM 2024 TO 2031
FIGURE 16 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET IN 2024 AND 2031
FIGURE 17 MARKET OVERVIEW
FIGURE 18 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2023
FIGURE 19 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 20 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2023
FIGURE 23 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 24 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 25 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2023
FIGURE 27 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2024-2031 (USD THOUSAND)
FIGURE 28 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, CAGR (2024-2031)
FIGURE 29 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 30 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2023
FIGURE 31 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2024-2031 (USD THOUSAND)
FIGURE 32 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, CAGR (2024-2031)
FIGURE 33 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, LIFELINE CURVE
FIGURE 34 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2023
FIGURE 35 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 36 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 37 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 38 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2023
FIGURE 39 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 40 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 41 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 NORTH AMERICA MULTIPLE HEREDITY EXOSTOSIS MARKET: SNAPSHOT (2023)
FIGURE 43 NORTH AMERICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
